Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Liabilities (2016 - 2025)

Protalix BioTherapeutics has reported Total Liabilities over the past 16 years, most recently at $34.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $34.1 million for Q4 2025, up 12.94% from a year ago — trailing twelve months through Dec 2025 was $34.1 million (up 12.94% YoY), and the annual figure for FY2025 was $34.1 million, up 12.94%.
  • Total Liabilities for Q4 2025 was $34.1 million at Protalix BioTherapeutics, up from $29.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for PLX hit a ceiling of $104.4 million in Q2 2021 and a floor of $28.6 million in Q2 2025.
  • Median Total Liabilities over the past 5 years was $61.5 million (2024), compared with a mean of $57.7 million.
  • Biggest five-year swings in Total Liabilities: rose 27.41% in 2024 and later tumbled 54.6% in 2025.
  • Protalix BioTherapeutics' Total Liabilities stood at $79.7 million in 2021, then dropped by 16.65% to $66.4 million in 2022, then dropped by 23.43% to $50.9 million in 2023, then tumbled by 40.62% to $30.2 million in 2024, then rose by 12.94% to $34.1 million in 2025.
  • The last three reported values for Total Liabilities were $34.1 million (Q4 2025), $29.4 million (Q3 2025), and $28.6 million (Q2 2025) per Business Quant data.